Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease
- PMID: 24468113
- PMCID: PMC3912487
- DOI: 10.1186/2051-5960-2-12
Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease
Abstract
Background: The accumulation of beta amyloid (Aβ) peptides, a hallmark of Alzheimer's disease (AD) is related to mechanisms leading to neurodegeneration. Among its pleiotropic cellular effects, Aβ accumulation has been associated with a deregulation of sphingolipid metabolism. Sphingosine 1-phosphate (S1P) derived from sphingosine is emerging as a critical lipid mediator regulating various biological activities including cell proliferation, survival, migration, inflammation, or angiogenesis. S1P tissue level is low and kept under control through equilibrium between its synthesis mostly governed by sphingosine kinase-1 (SphK1) and its degradation by sphingosine 1-phosphate lyase (SPL). We have previously reported that Aβ peptides were able to decrease the activity of SphK1 in cell culture models, an effect that could be blocked by the prosurvival IGF-1/IGF-1R signaling.
Results: Herein, we report for the first time the expression of both SphK1 and SPL by immunohistochemistry in frontal and entorhinal cortices from 56 human AD brains. Immunohistochemical analysis revealed a decreased expression of SphK1 and an increased expression of SPL both correlated to amyloid deposits in the entorhinal cortex. Otherwise, analysis of brain tissue extracts showed a decrease of SphK1 expression in AD brains whereas SPL expression was increased. The content of IGF-1R, an activator of SphK1, was found decreased in AD brains as well as S1P1, the major receptor for S1P.
Conclusions: Collectively, these results highlight the importance of S1P in AD suggesting the existence of a global deregulation of S1P signaling in this disease from its synthesis by SphK1 and degradation by SPL to its signaling by the S1P1 receptor.
Figures





Similar articles
-
Neuronal sphingosine kinase 2 subcellular localization is altered in Alzheimer's disease brain.Acta Neuropathol Commun. 2018 Apr 3;6(1):25. doi: 10.1186/s40478-018-0527-z. Acta Neuropathol Commun. 2018. PMID: 29615132 Free PMC article.
-
Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis.Acta Neuropathol Commun. 2014 Jan 23;2:9. doi: 10.1186/2051-5960-2-9. Acta Neuropathol Commun. 2014. PMID: 24456642 Free PMC article.
-
Sphingosine kinases/sphingosine-1-phosphate and death Signalling in APP-transfected cells.Neurochem Res. 2014 Apr;39(4):645-52. doi: 10.1007/s11064-014-1240-3. Epub 2014 Jan 23. Neurochem Res. 2014. PMID: 24452756 Free PMC article.
-
Sphingolipids in pulmonary fibrosis.Adv Biol Regul. 2015 Jan;57:55-63. doi: 10.1016/j.jbior.2014.09.008. Epub 2014 Oct 13. Adv Biol Regul. 2015. PMID: 25446881 Free PMC article. Review.
-
Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer.Int J Mol Sci. 2017 Oct 8;18(10):2109. doi: 10.3390/ijms18102109. Int J Mol Sci. 2017. PMID: 28991193 Free PMC article. Review.
Cited by
-
The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives.Cells. 2020 Jun 22;9(6):1515. doi: 10.3390/cells9061515. Cells. 2020. PMID: 32580348 Free PMC article. Review.
-
Extracellular Lipids in the Lung and Their Role in Pulmonary Fibrosis.Cells. 2022 Apr 3;11(7):1209. doi: 10.3390/cells11071209. Cells. 2022. PMID: 35406772 Free PMC article. Review.
-
Sphingolipids in neurodegeneration (with focus on ceramide and S1P).Adv Biol Regul. 2018 Dec;70:51-64. doi: 10.1016/j.jbior.2018.09.013. Epub 2018 Sep 22. Adv Biol Regul. 2018. PMID: 30287225 Free PMC article. Review.
-
Lipids and Alzheimer's Disease.Int J Mol Sci. 2020 Feb 22;21(4):1505. doi: 10.3390/ijms21041505. Int J Mol Sci. 2020. PMID: 32098382 Free PMC article. Review.
-
SCG5 and MITF may be novel markers of copper metabolism immunorelevance in Alzheimer's disease.Sci Rep. 2024 Jun 13;14(1):13619. doi: 10.1038/s41598-024-64599-z. Sci Rep. 2024. PMID: 38871989 Free PMC article.
References
-
- Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;2:5–36. - PubMed
-
- Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;2:239–259. - PubMed
-
- Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;2:1791–1800. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical